NO2024005I1 - Combination of trifluridine and tipiracil or a salt thereof with bevacizumab - Google Patents
Combination of trifluridine and tipiracil or a salt thereof with bevacizumabInfo
- Publication number
- NO2024005I1 NO2024005I1 NO2024005C NO2024005C NO2024005I1 NO 2024005 I1 NO2024005 I1 NO 2024005I1 NO 2024005 C NO2024005 C NO 2024005C NO 2024005 C NO2024005 C NO 2024005C NO 2024005 I1 NO2024005 I1 NO 2024005I1
- Authority
- NO
- Norway
- Prior art keywords
- tipiracil
- trifluridine
- bevacizumab
- salt
- combination
- Prior art date
Links
- 229960000397 bevacizumab Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- QQHMKNYGKVVGCZ-UHFFFAOYSA-N tipiracil Chemical compound N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 QQHMKNYGKVVGCZ-UHFFFAOYSA-N 0.000 title 1
- 229960002952 tipiracil Drugs 0.000 title 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 title 1
- 229960003962 trifluridine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013184684 | 2013-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2024005I1 true NO2024005I1 (no) | 2024-01-25 |
Family
ID=52628493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2024005C NO2024005I1 (no) | 2013-09-06 | 2024-01-25 | Combination of trifluridine and tipiracil or a salt thereof with bevacizumab |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9943537B2 (no) |
| EP (2) | EP3042669B1 (no) |
| JP (2) | JP6425653B2 (no) |
| KR (1) | KR101993963B1 (no) |
| AU (1) | AU2014316030B2 (no) |
| CY (1) | CY1126037T1 (no) |
| DK (1) | DK3042669T3 (no) |
| ES (1) | ES2946472T3 (no) |
| FI (2) | FI3042669T3 (no) |
| FR (1) | FR24C1005I1 (no) |
| HR (1) | HRP20230523T1 (no) |
| HU (2) | HUE062034T2 (no) |
| LT (1) | LT3042669T (no) |
| NO (1) | NO2024005I1 (no) |
| PL (1) | PL3042669T3 (no) |
| PT (1) | PT3042669T (no) |
| RS (1) | RS64243B1 (no) |
| RU (1) | RU2682161C2 (no) |
| SI (1) | SI3042669T1 (no) |
| TW (1) | TWI641385B (no) |
| WO (1) | WO2015034032A1 (no) |
| ZA (1) | ZA201602258B (no) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64243B1 (sr) | 2013-09-06 | 2023-06-30 | Taiho Pharmaceutical Co Ltd | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta |
| US11612653B2 (en) | 2016-01-08 | 2023-03-28 | Taiho Pharmaceutical Co., Ltd. | Anti-tumor agent containing immunomodulator, and antitumor effect potentiator |
| WO2017178428A1 (en) * | 2016-04-13 | 2017-10-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer |
| CN111032092A (zh) * | 2017-06-30 | 2020-04-17 | 韩国科学技术院 | Vegf-grab蛋白与药物的缀合物及其用途 |
| KR20220154986A (ko) | 2021-05-14 | 2022-11-22 | 윤상은 | 휴대용 마스크끈 절단기 |
| AR127893A1 (es) * | 2021-12-10 | 2024-03-06 | Servier Lab | Terapia del cáncer dirigida a egfr |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3088757B2 (ja) | 1995-03-29 | 2000-09-18 | 大鵬薬品工業株式会社 | ウラシル誘導体並びにそれを含有する抗腫瘍効果増強剤及び抗腫瘍剤 |
| US7312243B1 (en) * | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
| AU2006209547C1 (en) | 2005-01-26 | 2022-04-07 | Taiho Pharmaceutical Co., Ltd. | Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor |
| US7799783B2 (en) * | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| AU2014245146B2 (en) | 2013-03-27 | 2017-08-31 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent including irinotecan hydrochloride hydrate |
| WO2014157444A1 (ja) | 2013-03-27 | 2014-10-02 | 大鵬薬品工業株式会社 | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 |
| RS64243B1 (sr) | 2013-09-06 | 2023-06-30 | Taiho Pharmaceutical Co Ltd | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta |
-
2014
- 2014-09-05 RS RS20230421A patent/RS64243B1/sr unknown
- 2014-09-05 JP JP2015535524A patent/JP6425653B2/ja active Active
- 2014-09-05 HR HRP20230523TT patent/HRP20230523T1/hr unknown
- 2014-09-05 RU RU2016112421A patent/RU2682161C2/ru active
- 2014-09-05 LT LTEPPCT/JP2014/073436T patent/LT3042669T/lt unknown
- 2014-09-05 TW TW103130882A patent/TWI641385B/zh active
- 2014-09-05 FI FIEP14842538.2T patent/FI3042669T3/fi active
- 2014-09-05 EP EP14842538.2A patent/EP3042669B1/en active Active
- 2014-09-05 US US14/916,878 patent/US9943537B2/en active Active
- 2014-09-05 SI SI201432026T patent/SI3042669T1/sl unknown
- 2014-09-05 KR KR1020167005952A patent/KR101993963B1/ko active IP Right Grant
- 2014-09-05 ES ES14842538T patent/ES2946472T3/es active Active
- 2014-09-05 PT PT148425382T patent/PT3042669T/pt unknown
- 2014-09-05 DK DK14842538.2T patent/DK3042669T3/da active
- 2014-09-05 HU HUE14842538A patent/HUE062034T2/hu unknown
- 2014-09-05 EP EP23154967.6A patent/EP4201424A1/en active Pending
- 2014-09-05 AU AU2014316030A patent/AU2014316030B2/en active Active
- 2014-09-05 WO PCT/JP2014/073436 patent/WO2015034032A1/ja active Application Filing
- 2014-09-05 PL PL14842538.2T patent/PL3042669T3/pl unknown
-
2016
- 2016-04-05 ZA ZA2016/02258A patent/ZA201602258B/en unknown
-
2018
- 2018-01-15 JP JP2018004516A patent/JP6557744B2/ja active Active
-
2023
- 2023-06-07 CY CY20231100271T patent/CY1126037T1/el unknown
-
2024
- 2024-01-24 FR FR24C1005C patent/FR24C1005I1/fr active Active
- 2024-01-24 HU HUS2400001C patent/HUS2400001I1/hu unknown
- 2024-01-25 NO NO2024005C patent/NO2024005I1/no unknown
- 2024-01-25 FI FIC20240002C patent/FIC20240002I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20230003I1 (fi) | Efgartigimodi alfa | |
| NL301154I2 (nl) | Mometason of een zout daarvan en olopatadine of een zout daarvan | |
| DK3043784T3 (da) | Arylethere og anvendelser deraf | |
| BR302014001153S1 (pt) | Configuração aplicada em fechamento | |
| NO2024005I1 (no) | Combination of trifluridine and tipiracil or a salt thereof with bevacizumab | |
| FI20135956A (fi) | Kiinnitin | |
| DK2962100T3 (da) | Tuberkulosebiomarkører og anvendelser deraf | |
| DK3030549T3 (da) | Pyridazinonforbindelser og anvendelser deraf | |
| ES1087479Y (es) | Objeto de adorno | |
| DK2969131T3 (da) | Cos- og cs2-reduktionsfremgangsmåde | |
| DK2968528T3 (da) | Immunmodulation | |
| DK3089778T3 (da) | Ballonkateter | |
| BR112015023621A8 (pt) | derivados de meropenem e suas utilizações | |
| DK3047163T3 (da) | Lukkeelement | |
| FR3009951B1 (fr) | Prothese intra-laryngee | |
| FR3007291B1 (fr) | Composition cicatrisante et utlisation | |
| FI20145444A (fi) | Parvekerunko ja parveke | |
| FR3008575B1 (fr) | Flexible securise | |
| FI10349U1 (fi) | Tulvahälytyskokoonpano | |
| ES1078825Y (es) | Elemento de cerramiento | |
| TH148825B (th) | สารประกอบเตตระโซลิโนนและการใช้ของสิ่งนั้น | |
| TH1401006791B (th) | ฟิล์มโพลีเอสเตอร์และกรรมวิธีการผลิตนั้น | |
| TH1401005596A (th) | โพลิเอสเตอร์และวัตถุที่ผลิตขึ้นจากโพลิเอสเตอร์ดังกล่าว | |
| TH1401007378A (th) | โคโพลิเมอร์ที่มีอะซีทิดิเนียมเป็นส่วนประกอบและการใช้โพลิเมอร์ดังกล่าว | |
| ES2533927B1 (es) | Infiltrómetro inundador |